U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07105124) titled 'Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject' on April 24.
Brief Summary: A Trial to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics, of Sibeprenlimab Solution Administered Subcutaneously in Chinese Healthy Subjects
Study Start Date: Oct. 18, 2022
Study Type: INTERVENTIONAL
Condition:
Healthy Subjects (HS)
Intervention:
DRUG: Sibeprenlimab
Sibeprenlimab is being developed for the treatment of immunoglobulin A nephropathy (IgAN), an autoimmune glomerulonephritis characterized by the deposition of immunoglobulin (Ig) A-containing immune complexes in the kidney.
Recruitme...